date:Dec 12, 2012
mparable to that of breast-fed newborns.
This trial marks an important milestone in our clinical development program, positioning InFat as a premium fat blend for infant formulas, said Tzafra Cohen, Ph.D., CEO of Advanced Lipids. It shows Advanced Lipids commitment to our customers and the infant nutrition market to continued investment in research. We also anticipate finding additional benefits to the use of InFat.
Enzymotec says that InFat is a clinically-proven fat blend (beta-palmitate str